CS
CLYM

Credit Suisse’s Climb Bio CLYM Stock Holding History

Credit Suisse’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3
Closed – – 4350
2022
Q2 		$0 Buy
+3
New +$14 ﹤0.01% 4385

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AI
Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse's CLYM Position: Q3 2022 in Review

Credit Suisse sold out of Climb Bio (CLYM) in Q3 2022, closing a stake of 3 shares.

Credit Suisse first reported a position in CLYM in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 22 funds tracked by Wall St. Rank hold CLYM as of Q3 2022.

  • Credit Suisse reported no remaining Climb Bio position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 3 Climb Bio shares in Q3 2022.
  • Credit Suisse first reported a position in Climb Bio in Q2 2022 and held it in 1 quarter.
  • Credit Suisse's Climb Bio position peaked at $0 in Q2 2022.
  • 22 funds tracked by Wall St. Rank held Climb Bio as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.